Uddrag fra Reuters
Eli Lilly (LLY.N), opens new tab forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker’s shares down more than 8% on Tuesday.
The company said it had expected the market for the class of drugs known as incretins, which include both Zepbound and Mounjaro, to grow at a faster rate in the fourth quarter.
Lilly’s Zepbound and rival Novo Nordisk’s (NOVOb.CO), opens new tab Wegovy have experienced massive demand since they were approved, leading to short supply of both the medicines. Both the companies have been looking to ramp up manufacturing to meet demand.
Lilly said it expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively, according to data compiled by LSEG.
The company added that it expects 2025 sales between $58 billion and $61 billion, the midpoint of which was above analysts’ estimates of $58.52 billion
